July 31, 2019 – Evrys Bio awarded Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease

Evrys Bio awarded Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections” (5R44AI11407902).  Details are HERE